Key result
Naftopidil, doxazosin, and nifedipine dose-dependently inhibit platelet aggregation and calcium mobilization in vitro.
Why the study?
Further information was needed regarding the modes of action of doxazosin, naftopidil, and nifedipine on platelet function.
Do naftopidil, doxazosin, and nifedipine inhibit adrenaline and collagen-induced mobilization of platelet calcium and aggregation in vitro?
Do naftopidil, doxazosin, and nifedipine inhibit adrenaline and collagen-induced mobilization of platelet calcium and aggregation in vitro?
p-value: p=<0.05
Alpha 1-adrenoreceptor blockers naftopidil and doxazosin inhibit calcium mobilization in platelets, which may explain their ability to inhibit platelet aggregation.
May explain anti-aggregatory actions of alpha1-blockers; hypothesis-generating, no practice change indicated.
AIMS: The aim of the study was to obtain further information regarding the modes of action of doxazosin, naftopidil and nifedipine on platelet function. METHODS: We conducted an in vitro study of drug influences on adrenaline and collagen-induced mobilization of platelet calcium. RESULTS: In the presence of fibrinogen (300 micrograms ml-1) both collagen (5 micrograms ml-1) and adrenaline (16 microM) stimulated the aggregation of washed platelets. Collagen induced a transient rise (+4.97 +/- 0.63 microM) in platelet Ca2+ concentration, [Ca2+]i, as measured using the photoprotein aequorin, which coincided with the onset of aggregation. Adrenaline induced a smaller rise (+3.6 +/- 0.96 microM) which, however, occurred after the onset of aggregation. Naftopidil, an alpha 1-adrenoreceptor antagonist produced a concentration-dependent inhibition of collagen-induced Ca2+ mobilization, maximum inhibition (22.9 +/- 4%, P < 0.05) occurring with 40 microM naftopidil. The inhibition of Ca2+ mobilization was not reflected by a concentration-dependent inhibition of platelet aggregation, although 40 microM naftopidil produced statistically significant inhibition (23.3 +/- 11.7%, P < 0.05). The adrenaline-induced rise in [Ca2+]i was inhibited dose dependently by naftopidil (e.g. 40 microM naftopidil, 100 +/- 0%, P < 0.05), as was aggregation (40 microM naftopidil, 100 +/- 0%, P < 0.05). Doxazosin, another alpha 1-adrenoreceptor blocker, inhibited Ca2+ mobilization induced by collagen to similar extents as for naftopidil (30 microM doxazosin, 17.4 +/- 2.5%, P < 0.05), but did not inhibit platelet aggregation. It also inhibited the adrenaline-induced rise in [Ca2+]i in a concentration-dependent manner (30 microM doxazosin, 37.6 +/- 13.7%, P < 0.05), significant inhibitions of platelet aggregation also being produced (30 microM, 49.6 +/- 17.2%, P < 0.05). As expected, the calcium channel blocker nifedipine produced concentration-dependent inhibitions of both collagen-induced Ca2+ mobilization (e.g. 28 microM nifedipine, 47.8 +/- 2.7%, P < 0.05) and aggregation (28 microM, 55.1 +/- 9.2%, P < 0.05). CONCLUSIONS: These data indicate that the alpha 1-adrenoreceptor blockers, naftopidil and doxazosin, inhibit Ca2+ mobilization, this mechanism being possibly the means whereby these drugs inhibit platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Alarayyed et al. (1997) studied Platelet function. Naftopidil, doxazosin, and nifedipine was evaluated on Inhibition of collagen- and adrenaline-induced Ca2+ mobilization and platelet aggregation (p=<0.05). Naftopidil, doxazosin, and nifedipine produced concentration-dependent inhibitions of collagen- and adrenaline-induced platelet calcium mobilization and aggregation in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: